JETREA CARE Strives to Be Your Trusted Partner in Access and Reimbursement Support

Enroll your patients in JETREA CARE today

JETREA CARE Alert

JETREA® has a new J-code,
effective January 1, 2014
[Click here to learn more]

Coding & Billing information
updated for the Hospital
Outpatient Department (HOPD)

[Click here to learn more]

NEW resources available in
Forms & Documents
[Click here to learn more]

Coding and Billing information
updated for Physician Offices
[Click here to learn more]

NEW: Walgreens
Prescription/Pharmacy Intake Form
added to Forms & Documents
[Click here to learn more]

JETREA CARE collaborates with practices to offer services built around your needs:

Benefit Verification

To identify coverage

Reimbursement Support

To help your practice and find solutions for a variety of patient coverage scenarios

Co-pay and Assistance Programs

To help your patients with their out-of-pocket financial responsibility

Indication

JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.

Important Safety Information

Warnings and Precautions

  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).

Adverse Reactions

  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Please see full Prescribing Information for JETREA.